Equities Analysts Set Expectations for JANX Q3 Earnings

Key Points

• HC Wainwright raised Janux Therapeutics’ Q3 2026 EPS estimate to a loss of $0.45 per share from a previous loss estimate of $0.50. Its FY2026 estimate is a loss of $1.69 per share, versus the $1.71 consensus.
• Janux’s latest quarterly results fell short of expectations, with an EPS loss of $0.35 versus the estimated $0.25 loss and revenue of $10.27 million versus the $19.07 million consensus.
• Analyst sentiment remains a Moderate Buy, with nine Buy, three Hold, and two Sell ratings and an average price target of $37.58. Shares opened at $16.52, while institutional investors own 75.39% of the stock.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Janux Therapeutics in a report issued on Monday, August 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.45) per share for the quarter, up from their previous forecast of ($0.50). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.71) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.69) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.58) EPS, Q4 2027 earnings at ($0.69) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($1.11) EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million.

A number of other equities research analysts have also recently commented on the company. JonesTrading dropped their target price on Janux Therapeutics from $50.00 to $28.00 and set a "buy" rating on the stock in a research report on Tuesday, April 28th. Wedbush reduced their price target on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, May 8th. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a research report on Friday. Truist Financial reissued a "buy" rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Finally, Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $37.58.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $16.52 on Wednesday. The firm has a 50-day simple moving average of $15.14 and a two-hundred day simple moving average of $14.50. The company has a market cap of $1.01 billion, a P/E ratio of -10.07 and a beta of 2.50. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of JANX. AQR Capital Management LLC raised its holdings in shares of Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock valued at $262,000 after acquiring an additional 4,059 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Janux Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock worth $583,000 after purchasing an additional 3,393 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Janux Therapeutics by 12.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock valued at $5,033,000 after purchasing an additional 20,657 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Janux Therapeutics by 82.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company's stock valued at $5,715,000 after purchasing an additional 112,116 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Janux Therapeutics by 12.0% during the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company's stock worth $1,094,000 after purchasing an additional 5,055 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Janeen Noel Doyle sold 4,059 shares of the business's stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares of the company's stock, valued at $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is currently owned by company insiders.

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $1.69 from $1.89, closer to the consensus loss estimate of $1.71. The firm also narrowed projected losses for Q3 2026 to $0.45 from $0.50 and Q4 2026 to $0.51 from $0.52.
• Positive Sentiment: Forecasts for 2027 also improved in the first three quarters: Q1 EPS was revised to a loss of $0.53 from $0.56, Q2 to a loss of $0.56 from $0.59, and Q3 to a loss of $0.58 from $0.63. The FY2027 loss estimate improved to $2.36 from $2.44.
• Neutral Sentiment: The reported short-interest data showed zero shares sold short and a zero-day days-to-cover ratio, making it unreliable for assessing short-covering or bearish positioning.
• Negative Sentiment: HC Wainwright lowered its Q4 2027 EPS forecast to a loss of $0.69 from $0.66, FY2028 to a loss of $2.72 from $2.51, FY2029 to a loss of $1.11 from $1.00, and FY2030 profit to $0.97 from $1.06. These cuts suggest a weaker long-term earnings trajectory despite better near-term expectations.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source